List view / Grid view

Mark Egerton

Filter the results

 

news

Sunesis Pharmaceuticals selects Quotient Clinical’s real-time adaptive manufacturing to support its vosaroxin clinical mass balance/ADME program

Quotient Clinical, the Translational Pharmaceutics® Company, and Sunesis Pharmaceuticals have…

21 January 2015 | By kdm communications

Quotient Clinical, the Translational Pharmaceutics® Company, and Sunesis Pharmaceuticals have announced the initiation of a clinical mass balance/ADME trial for vosaroxin – a candidate therapeutic for acute myelogenous leukemia (AML)...

news

Quotient Clinical celebrates its 50th RapidFACT™ program

Quotient Clinical has commenced its 50th RapidFACT (Rapid Formulation development…

7 February 2014 | By kdm communications

Quotient Clinical has commenced its 50th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the development of this service...